Grifois (GRFS) Stock: Buy, Sell, or Hold?
GRFS - Grifois, S.A.
$7.56
0.11 (1.48%)
▲
5d:
-1.05%
30d:
+5.0%
90d:
-2.45%
BUY
MODERATE Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Sep 28, 2026
0d
Get Alerted When GRFS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: GRFS shows positive signals but monitor for confirmation. Market pricing in 3.1% decline. Moderate conviction.
💡 BUY OPPORTUNITY: GRFS shows positive signals but monitor for confirmation. Market pricing in 3.1% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$16.06
Based on 14.2% avg growth
INTRINSIC VALUE TODAY
$9.97
24.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 5.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GRFS is currently trading at $7.56, which is considered extended relative to its 30-day fair value range of $7.28 to $7.52. The stock's valuation (Forward PE: 5.2) is in line with its historical norms (5.8). Remarkably, the market is currently pricing in an annual earnings decline of 3.1% over the next few years. This pessimistic expectation contrasts with the company's recent 32.9% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, GRFS is showing sideways momentum. The price is approaching resistance at $7.75. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: GRFS scores 62/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $10.87 (+43.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GRFS is showing sideways momentum. The price is approaching resistance at $7.75. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: GRFS scores 62/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $10.87 (+43.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$7.28 -
$7.52
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (62/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 43.7% below Wall St target ($10.87)
- BULLISH: Bottoming setup score 62/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$7.28 -
$7.52
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$7.15
Resistance Level
$7.75
Current Trend
Sideways
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
5.24
Wall Street Target
$10.87
(+43.7%)
Revenue Growth (YoY)
-0.9%
Earnings Growth (YoY)
32.9%
Profit Margin
6.1%
Valuation Discount vs History
-3.1% cheaper
PE vs Historical
5.2 vs 5.8
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.1%
(market-implied from PE analysis)
1-Year Target
$7.33
(-3%)
2-Year Target
$7.10
(-6%)
3-Year Target
$6.88
(-9%)
3-Yr Target (if PE normalizes)
(PE: 5→6)
$7.61
(+1%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 24.3%)
$55.00
(+628%)
Base:
(SPY PE: 5.2, Growth: 24.3%)
$14.52
(+92%)
Bear:
(PE: 4.5, Growth: 24.3%)
$12.34
(+63%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (10x PE), but valuation improves significantly next year (5x PE) as earnings recover.
Trailing PE: 9.80 | Current EPS (TTM): $0.76
Bull Case
$15.55
(+106%)
Analyst growth 89.8%, PE expands to 10.8
Base Case
$14.14
(+87%)
Market implied 89.8%, PE stable at 9.8
Bear Case
$5.07
(-33%)
Severe decline -20.0%, PE contracts to 8.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 5.2 to 5.8
Stabilization Target:
$8.37
(+10.7%)
PE Expansion Potential:
+10.7%
Share & Embed Analysis
Last updated: October 23, 2026 6:34 PM ET
Data refreshes hourly during market hours. Next update: 7:34 PM
Data refreshes hourly during market hours. Next update: 7:34 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GRFS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ABBV
AbbVie Inc |
STRONG BUY
30 analysts |
$283 | 45 HOLD |
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1328 | 33 SELL |
|
MRK
Merck & Company Inc |
STRONG BUY
27 analysts |
$158 | 56 HOLD |
|
GILD
Gilead Sciences Inc |
STRONG BUY
28 analysts |
$160 | 41 HOLD |
|
BIIB
Biogen Inc |
BUY
36 analysts |
$244 | 43 HOLD |
